Is Amisulpride Used for ADHD?
Amisulpride, a selective dopamine D2/D3 receptor antagonist, is approved in various countries for schizophrenia and acute psychotic episodes but not for ADHD.[1] Some off-label studies and case reports explore low-dose amisulpride (50-100 mg/day) for ADHD symptoms due to its effects on dopamine signaling, which overlaps with ADHD pathophysiology.[2][3] Evidence is limited to small trials showing potential benefits in attention and impulsivity, but it's not standard treatment—stimulants like methylphenidate remain first-line.
Common Side Effects from Clinical Use
In psychiatric dosing (typically 400-800 mg/day for psychosis), side effects include:
- Extrapyramidal symptoms (tremor, rigidity, akathisia) in 10-20% of patients, dose-dependent.[1][4]
- Weight gain (average 1-2 kg over months), less than with other antipsychotics.[5]
- Hyperprolactinemia leading to galactorrhea, menstrual irregularities, or gynecomastia (up to 40% at higher doses).[1]
- Sedation, insomnia, or anxiety (5-15%).[4]
At low doses proposed for ADHD (under 200 mg/day), extrapyramidal effects and prolactin elevation drop significantly, with trials reporting nausea (10%), headache (8%), and mild sedation as most frequent.[2][3]
Side Effects Specific to ADHD Context
Limited ADHD-specific data from open-label studies (n<50) note:
- Appetite suppression and initial anxiety, mimicking stimulant side effects.[3]
- Rare dyskinesia or restlessness at doses above 100 mg.[2]
No long-term ADHD trials exist, so risks like tardive dyskinesia (cumulative with prolonged use) remain unquantified for this indication.[1]
Serious or Rare Risks
- QT prolongation (risk of arrhythmias), especially with heart conditions or other QT-prolonging drugs; monitor ECG.[1][4]
- Neuroleptic malignant syndrome (fever, rigidity, autonomic instability; <0.1%).[1]
- Suicidal ideation in young adults, per black-box warnings for antipsychotics.[6]
In ADHD patients (often children/teens), heightened vigilance needed for growth suppression or metabolic changes, though less pronounced than with atypicals like risperidone.[5]
Comparisons to ADHD Standard Treatments
Unlike stimulants (e.g., Adderall: insomnia, appetite loss, cardiovascular strain), amisulpride avoids abuse potential but adds prolactin and movement disorder risks.[3] Non-stimulants like atomoxetine cause fatigue/nausea without extrapyramidal effects.[7] Low-dose amisulpride may suit stimulant-intolerant patients but lacks robust comparative trials.
Patient and Monitoring Concerns
Start low (25-50 mg/day) if trialed off-label; monitor prolactin, weight, and EPS monthly initially.[2] Not recommended in pregnancy (category C) or with epilepsy. Consult psychiatrist—ADHD guidelines (e.g., AACAP) do not endorse antipsychotics as monotherapy.[7]
[1]: Drugs.com - Amisulpride
[2]: PubMed - Low-dose amisulpride in ADHD (2018 trial)
[3]: J Clin Psychopharmacol - Amisulpride for ADHD symptoms (case series)
[4]: EMA Product Information - Solian (amisulpride)
[5]: World Psychiatry - Antipsychotic weight gain meta-analysis
[6]: FDA - Antipsychotic suicidality warning
[7]: AACAP Practice Parameters for ADHD